Myriad Genetics is a genetic testing company focused on hereditary cancer risk, prenatal screening, oncology, and mental health pharmacogenomics. The company provides germline and tumor genomic testing to guide cancer risk assessment, treatment decisions, and prevention strategies, with a global reach including the United States and international locations. Its offerings include a broad catalog of genetic tests and patient/provider resources designed to support diagnosis, prognosis, and personalized care across multiple health areas. Headquartered in the United States, Myriad emphasizes actionable genetic insights to improve patient outcomes and advance precision medicine.
No recent deals for this company.